Silence Therapeutics plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Iain Gladstone Ross
- Full Time Employees
- 88
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 72 Hammersmith Road London GL United Kingdom W6 7AP
- IPO Date
- Sep 8, 2020
- CIK
- 0001479615
- Website
- silence-therapeutics.com
- Similar Companies
- Business
- Silence Therapeutics plc (Nasdaq: SLN), founded in 1994 and headquartered in Hammersmith, London, with additional offices in Hoboken, New Jersey, USA, and Berlin, Germany, develops proprietary short interfering RNA (siRNA) therapeutics utilizing its mRNAi GOLD™ platform to silence disease-causing genes in the liver for the treatment of rare and cardiovascular diseases. The company advances a wholly owned clinical pipeline including divesiran (SLN124), an siRNA targeting TMPRSS6 for hematological disorders such as beta-thalassemia and myelodysplastic syndromes; zerlasiran (formerly SLN360), an siRNA designed to reduce elevated lipoprotein(a) levels associated with cardiovascular risk, which demonstrated up to 99% reduction in Phase 1 studies lasting 90 days post-dosing; and other candidates like SLN-312, SLN-548 targeting rare diseases. It also licenses siRNA product candidates through partnerships, notably a collaboration with AstraZeneca featuring an ongoing Phase 1 study of SLN312 in an undisclosed indication, alongside prior agreements with Mallinckrodt Pharmaceuticals and Hansoh Pharma. Recent developments encompass pipeline progression with positive clinical data for zerlasiran reported in November 2023, quarterly financial updates through 2025 showing cash reserves exceeding $114 million to support operations into 2028, and strategic focus on high-unmet-need areas in hematology, cardiovascular disease, and rare disorders. Silence Therapeutics operates globally, partnering with pharmaceutical companies to expand its RNAi technology applications across therapeutic areas.
Company News
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile